FBLG Q3 2024 Earnings — FibroBiologics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

FBLGFibroBiologics, Inc. Common Stock

$17M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$3M

Net Income

-$500,000

EPS (Diluted)

$-0.01

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$571,000

Balance Sheet

Total Assets

$10M

Total Liabilities

$8M

Stockholders' Equity

$3M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$3M	-$2M	-63.4%
Net Income	-$500,000	-$2M	+77.2%